

## Datasheet: BUF012B

<b>Description:</b>	alamarBlue®
<b>Name:</b>	alamarBlue®
<b>Format:</b>	Reagent
<b>Product Type:</b>	Accessory Reagent
<b>Quantity:</b>	100 ml

## Product Details

### Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

	Yes	No	Not Determined	Suggested Dilution
ELISA	▪			
Immunofluorescence	▪			
Functional Assays	▪			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

### Product Form

Liquid.

### Preservative Stabilisers

None present.

### Product Information

The cell proliferation assay reagent alamarBlue® is designed to provide a rapid and sensitive measure of cell proliferation and cytotoxicity in various human and animal cell lines, bacteria and fungi.

alamarBlue® is an indicator dye, that incorporates an oxidation-reduction (REDOX) indicator that both fluoresces and changes colour in response to the chemical reduction of growth medium, resulting from cell growth. The alamarBlue® cell proliferation assay reagent is designed to quantitatively measure the proliferation of various human and animal cell lines, bacteria and fungi.

**Some variability in the absorbance may occur between batches of alamarBlue® but all batches should fall between 0.84 and 0.95AU when measured between 600nm and 602nm on a spectrophotometer.**

Please view the full [cell proliferation assay instructions](#).

[Colorimetric and Fluorescence result calculators](#) are available here.

This site includes:

Frequently Asked Questions

Example calculations

Product-related references.

---

**Test Principle**

Cell proliferation assay

- Growing cells cause a chemical reduction of AlamarBlue.
- Continued growth maintains a reduced environment. (fluorescent, red).
- Inhibition of growth maintains an oxidized environment. (non-fluorescent, blue).
- Data may be collected using either fluorescence-based or absorbance-based instrumentation.
- Fluorescence is monitored at 530-560nm excitation wavelength and 590nm emission wavelength.
- Absorbance is monitored at 570nm and 600nm.

---

**Intended Use**

- Cell proliferation assays.
- The reagent can be used to establish proliferation or relative cytotoxicity in a cell proliferation assay.
- Baseline data for predicting the toxicity of related novel agents can be compared to baseline data with known *in-vivo* toxicity.
- AlamarBlue<sup>®</sup> is for use between pH6.8 and pH7.4.

---

**Instructions For Use**

Instructions for use can be found at [www.bio-rad-antibodies.com/uploads/IFU/BUF012B.pdf](http://www.bio-rad-antibodies.com/uploads/IFU/BUF012B.pdf).

---

**References**

1. Nakayama, G.R. *et al.* (1997) Assessment of the Alamar Blue assay for cellular growth and viability in vitro. [J Immunol Methods. 204: 205-8.](#)
2. Latham, J.P. *et al.* (2000) Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector. [Cancer Res. 60: 334-41.](#)
3. McCormick, A.L. *et al.* (2001) Immunization with an interferon-gamma-gp120 fusion protein induces enhanced immune responses to human immunodeficiency virus gp120. [J Infect Dis. 184: 1423-30.](#)
4. Brieger, A. *et al.* (2002) Transient mismatch repair gene transfection for functional analysis of genetic hMLH1 and hMSH2 variants. [Gut. 51: 677-84.](#)
5. Naughton, P. *et al.* (2002) Induction of heme oxygenase 1 by nitrosative stress. A role for nitroxyl anion. [J Biol Chem. 277: 40666-74.](#)
6. Scapagnini, G. *et al.* (2002) Caffeic acid phenethyl ester and curcumin: a novel class of heme oxygenase-1 inducers. [Mol Pharmacol. 61: 554-61.](#)
7. Tiwari, A. *et al.* (2002) Development of a hybrid cardiovascular graft using a tissue engineering approach. [FASEB J. 16: 791-6.](#)
8. Guo, Y. *et al.* (2002) An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer. [Cancer Res. 62: 4678-84.](#)
9. Borg, S.A. *et al.* (2003) Expression of interleukin-6 and its effects on growth of HP75

- human pituitary tumor cells. [J Clin Endocrinol Metab. 88: 4938-44.](#)
10. Dawson, C.W. *et al.* (2003) Epstein-Barr virus latent membrane protein 1 (LMP1) activates the phosphatidylinositol 3-kinase/Akt pathway to promote cell survival and induce actin filament remodeling. [J Biol Chem. 278: 3694-704.](#)
11. Ferro, V.A. *et al.* (2003) *In vitro* susceptibilities of *Shigella flexneri* and *Streptococcus pyogenes* to inner gel of *Aloe barbadensis* Miller. [Antimicrob Agents Chemother. 47: 1137-9.](#)
12. Habtemariam, S. *et al.* (2003) *In vitro* antileishmanial effects of antibacterial diterpenes from two Ethiopian *Premna* species: *P. schimperi* and *P. oligotricha*. [BMC Pharmacol. 3:6.](#)
13. Roghanian, A. *et al.* (2006) Inflammatory lung secretions inhibit dendritic cell maturation and function via neutrophil elastase. [Am J Respir Crit Care Med. 174: 1189-98.](#)
14. Prakash, J. *et al.* (2006) Intracellular delivery of the p38 mitogen-activated protein kinase inhibitor SB202190 [4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole] in renal tubular cells: a novel strategy to treat renal fibrosis. [J Pharmacol Exp Ther. 319: 8-19.](#)
15. Feder-Mengus, C. *et al.* (2007) Multiple mechanisms underlie defective recognition of melanoma cells cultured in three-dimensional architectures by antigen-specific cytotoxic T lymphocytes. [Br J Cancer. 96: 1072-82.](#)
16. Juillerat-Jeanneret, L. *et al.* (2008) Heterogeneity of human glioblastoma: glutathione-S-transferase and methylguanine-methyltransferase. [Cancer Invest. 26 \(6\): 597-609.](#)
17. Carroll, J. *et al.* (2009) Optimization of a rapid viability assay for *Mycobacterium avium* subsp. *paratuberculosis* by using alamarBlue. [Appl Environ Microbiol. 75: 7870-2.](#)
18. Wu, G. *et al.* (2010) A chimeric protein that functions as both an anthrax dual-target antitoxin and a trivalent vaccine. [Antimicrob Agents Chemother. 54: 4750-7.](#)
19. Cao, S. *et al.* (2010) Residue histidine 669 is essential for the catalytic activity of *Bacillus anthracis* lethal factor. [J Bacteriol. 192: 5799-805.](#)
20. Scotter, E.L. *et al.* (2010) Neuroprotective potential of CB1 receptor agonists in an *in vitro* model of Huntington's disease. [Br J Pharmacol. 160: 747-61.](#)
21. Lara, D. *et al.* (2010) Anti-trypanosomatid activity of ceragenins. [J Parasitol. 96 \(3\): 638-42.](#)
22. Xiao, P. *et al.* (2010) *Aspergillus fumigatus* flbB encodes two basic leucine zipper domain (bZIP) proteins required for proper asexual development and gliotoxin production. [Eukaryot Cell. 9: 1711-23.](#)
23. Lee, do Y. *et al.* (2010) Activation of PERK signaling attenuates Abeta-mediated ER stress. [PLoS One. 5: e10489.](#)
24. Lewis, C.S. *et al.* (2010) Local Antibiotic Delivery with Bovine Cancellous Chips. [J Biomater Appl. 26: 491-506.](#)
25. Goren, A. *et al.* (2010) Encapsulated human mesenchymal stem cells: a unique hypoinmunogenic platform for long-term cellular therapy. [FASEB J. 24: 22-31.](#)
26. Golay, J. *et al.* (2010) Possible misinterpretation of the mode of action of therapeutic antibodies *in vitro*: homotypic adhesion and flow cytometry result in artefactual direct cell death [Blood 116:3372-3.](#)
27. Misra, S.K. *et al.* (2010) Effect of nanoparticulate bioactive glass particles on bioactivity and cytocompatibility of poly(3-hydroxybutyrate) composites. [J R Soc Interface. 7: 453-65.](#)
28. Sagar, J. *et al.* (2010) Lowering the apoptotic threshold in colorectal cancer cells by targeting mitochondria. [Cancer Cell Int. 10: 31.](#)

29. Mansour, N.R. and Bickle, Q.D. (2010) Comparison of microscopy and Alamar blue reduction in a larval based assay for schistosome drug screening. [PLoS Negl Trop Dis. 4: e795.](#)
30. Hsu, D.S. *et al.* (2010) Regulation of excision repair cross-complementation group 1 by Snail contributes to cisplatin resistance in head and neck cancer. [Clin Cancer Res. 16: 4561-71.](#)
31. Garces, A. *et al.* (2010) EspA acts as a critical mediator of ESX1-dependent virulence in Mycobacterium tuberculosis by affecting bacterial cell wall integrity. [PLoS Pathog. 6\(6\): e1000957.](#)
32. Genetos, D.C. *et al.* (2010) Oxygen tension modulates neurite outgrowth in PC12 cells through a mechanism involving HIF and VEGF. [J Mol Neurosci. 40: 360-6.](#)
33. Landgraf, K.E. *et al.* (2010) Allosteric peptide activators of pro-hepatocyte growth factor stimulate Met signaling. [J Biol Chem. 285: 40362-72.](#)
34. Rzhepishevskaya, O. *et al.* (2011) The antibacterial activity of ga3+ is influenced by ligand complexation as well as the bacterial carbon source. [Antimicrob Agents Chemother. 55: 5568-80.](#)
35. Uitdehaag, J.C. *et al.* (2011) Multidimensional Profiling of CSF1R Screening Hits and Inhibitors: Assessing Cellular Activity, Target Residence Time, and Selectivity in a Higher Throughput Way. [J Biomol Screen. 16: 1007-17.](#)
36. Rao, T.D. *et al.* (2011) Dual-Fluorescence Isogenic High-Content Screening for MUC16/CA125 Selective Agents. [Mol Cancer Ther. 10: 1939-48.](#)
37. Voloshin, T. *et al.* (2011) G-CSF supplementation with chemotherapy can promote revascularization and subsequent tumor regrowth: prevention by a CXCR4 antagonist. [Blood. 118: 3426-35.](#)
38. Arlian, B.M. and Tinker, J.K. (2011) Mucosal Immunization with a Staphylococcus aureus IsdA-Cholera Toxin A2/B Chimera Induces Antigen-Specific Th2-Type Responses in Mice. [Clin Vaccine Immunol. 18: 1543-51.](#)
39. Lau, L.I. *et al.* (2011) The Effect of Photooxidative Stress and Inflammatory Cytokine on Complement Factor H Expression in Retinal Pigment Epithelial Cells. [Invest Ophthalmol Vis Sci. 52: 6832-41.](#)
40. Xu, S. *et al.* (2011) Marek's disease virus type 1 microRNA miR-M3 suppresses cisplatin-induced apoptosis by targeting Smad2 of the transforming growth factor beta signal pathway. [J Virol. 2011 Jan;85\(1\):276-85.](#)
41. Lakhkar, N. *et al.* (2011) Titanium and strontium-doped phosphate glasses as vehicles for strontium ion delivery to cells. [J Biomater Appl. 25: 877-93.](#)
42. Suter, S.E. *et al.* (2011) FLT3 mutations in canine acute lymphocytic leukemia. [BMC Cancer. 11: 38.](#)
43. Wilson, B.A. *et al.* (2011) High-throughput screen identifies novel inhibitors of cancer biomarker  $\alpha$ -methylacyl coenzyme A racemase (AMACR/P504S). [Mol Cancer Ther. 10: 825-38.](#)
44. Goetzenich, A. *et al.* (2011) The effects of metoprolol on hypoxia- and isoflurane-induced cardiac late-phase preconditioning. [Acta Anaesthesiol Scand. 55 \(7\): 862-9.](#)
45. Tao, L. and Yu, J.H. (2011) AbaA and WetA govern distinct stages of *Aspergillus fumigatus* development. [Microbiology. 157: 313-26.](#)
46. Alsford, S. and Horn, D. (2011) Elongator Protein 3b Negatively Regulates Ribosomal DNA Transcription in African Trypanosomes. [Mol Cell Biol. 31: 1822-32.](#)
47. Crilly, A. *et al.* (2011) Phosphodiesterase 4 (PDE4) regulation of proinflammatory

- cytokine and chemokine release from rheumatoid synovial membrane. [Ann Rheum Dis. 70: 1130-7.](#)
48. Paget, C. *et al.* (2011) Potential Role of Invariant NKT Cells in the Control of Pulmonary Inflammation and CD8+ T Cell Response during Acute Influenza A Virus H3N2 Pneumonia. [J Immunol. 186: 5590-602.](#)
49. Diril, M.K. *et al.* (2012) Cyclin-dependent kinase 1 (Cdk1) is essential for cell division and suppression of DNA re-replication but not for liver regeneration. [Proc Natl Acad Sci U S A. 109: 3826-31.](#)
50. Warriar, T. *et al.* (2012) Antigen 85C inhibition restricts Mycobacterium tuberculosis growth through disruption of cord factor biosynthesis. [Antimicrob Agents Chemother. 56: 1735-43.](#)
51. Looi, C.Y. *et al.* (2013) Induction of apoptosis in human breast cancer cells via caspase pathway by vernodalin isolated from *Centratherum anthelminticum* (L.) seeds. [PLoS One. 8 \(2\): e56643.](#)
52. Dreidax, D. *et al.* (2013) Low p14ARF expression in neuroblastoma cells is associated with repressed histone mark status, and enforced expression induces growth arrest and apoptosis. [Hum Mol Genet. 22: 1735-45.](#)
53. Cui, Y.X. *et al.* (2013) A new methodological sequence to expand and transdifferentiate human umbilical cord blood derived CD133+ cells into a cardiomyocyte-like phenotype. [Stem Cell Rev Rep. 9 \(3\): 350-9.](#)
54. Ardakani, A.G. *et al.* (2014) Quantifying the correlation between spatially defined oxygen gradients and cell fate in an engineered three-dimensional culture model. [J R Soc Interface. 11. pii: 20140501.](#)
55. Wang, H. *et al.* (2014) Enhanced osteoblast responses to poly ether ether ketone surface modified by water plasma immersion ion implantation. [Colloids Surf B Biointerfaces. 117: 89-97.](#)
56. Deschamps, E. *et al.* (2014) Characterization of indoor dust from Brazil and evaluation of the cytotoxicity in A549 lung cells. [Environ Geochem Health. 36 \(2\): 225-33.](#)
57. Bernardini, F.P. *et al.* (2015) Superficial Enhanced Fluid Fat Injection (SEFFI) to Correct Volume Defects and Skin Aging of the Face and Periocular Region. [Aesthet Surg J. 35 \(5\): 504-15.](#)
58. Moreira, Â *et al.* (2015) Adipocyte secreted factors enhance aggressiveness of prostate carcinoma cells. [PLoS One. 10 \(4\): e0123217.](#)
59. Bertoldi, S. *et al.* (2015) Exploiting novel sterilization techniques for porous polyurethane scaffolds. [J Mater Sci Mater Med. 26 \(5\): 182.](#)
60. Rao, T.D. *et al.* (2015) Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion. [PLoS One. 10 \(5\): e0126633.](#)
61. Howe, G.A. *et al.* (2016) Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer. [PLoS One. 11 \(3\): e0150567.](#)
62. Botero A *et al.* (2016) *In vitro* drug susceptibility of two strains of the wildlife trypanosome, *Trypanosoma copemani*: A comparison with *Trypanosoma cruzi*. [Int J Parasitol Drugs Drug Resist. 7 \(1\): 34-41.](#)
63. Yu, H.C. *et al.* (2016) Effects of fibroblast growth factor-2 on cell proliferation of cementoblasts. [J Dent Sci. 11 \(4\): 463-7.](#)
64. Grasy, J. *et al.* (2016) Content of Soluble Factors and Characteristics of Stromal Vascular Fraction Cells in Lipoaspirates from Different Subcutaneous Adipose Tissue

- Depots. [Aesthet Surg J. 36 \(7\): 831-41.](#)
65. van Driel, P.B. *et al.* (2016) EGFR targeted nanobody-photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer. [J Control Release. 229: 93-105.](#)
66. Howe GA *et al.* (2016) Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer. [PLoS One. 11 \(3\): e0150567.](#)
67. van Driel, P.B. *et al.* (2016) EGFR targeted nanobody-photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer. [J Control Release. 229: 93-105.](#)
68. Chauhan, S. *et al.* (2016) Cdk2 catalytic activity is essential for meiotic cell division *in vivo*. [Biochem J. 473 \(18\): 2783-98.](#)
69. Drong, C. *et al.* (2017) Effects of monensin and essential oils on immunological, haematological and biochemical parameters of cows during the transition period. [J Anim Physiol Anim Nutr \(Berl\). 101 \(4\): 791-806.](#)
70. Xu, S. *et al.* (2016) MicroRNA-33 promotes the replicative senescence of mouse embryonic fibroblasts by suppressing CDK6. [Biochem Biophys Res Commun. 473 \(4\): 1064-70.](#)
71. Li, G. *et al.* (2017) Antimicrobial susceptibility and MIC distribution of 41 drugs against clinical isolates from China and reference strains of nontuberculous mycobacteria. [Int J Antimicrob Agents. 49 \(3\): 364-74.](#)
72. Lee, Y.W. *et al.* (2017) Effects of Redox Modulation on Cell Proliferation, Viability, and Migration in Cultured Rat and Human Tendon Progenitor Cells. [Oxid Med Cell Longev. 2017: 8785042.](#)
73. DiSpigna, G. *et al.* (2017) Human cardiac multipotent adult stem cells in 3D matrix: new approach of tissue engineering in cardiac regeneration post-infarction. [J Biol Regul Homeost Agents. 31 \(4\): 911-21.](#)
74. Martínez-morcillo, S. *et al.* (2018) The organophosphorus pesticide dimethoate decreases cell viability and induces changes in different biochemical parameters of rat pancreatic stellate cells. [Toxicol In Vitro. 54: 89-97.](#)
75. Calejo, I. *et al.* (2019) A Textile Platform Using Continuous Aligned and Textured Composite Microfibers to Engineer Tendon-to-Bone Interface Gradient Scaffolds. [Adv Healthc Mater. 8 \(15\): e1900200.](#)
76. Scialla, S. *et al.* (2019) Bioactive chitosan-based scaffolds with improved properties induced by dextran-grafted nano-maghemite and l-arginine amino acid. [J Biomed Mater Res A. 107 \(6\): 1244-52.](#)
77. Jyotsana, N. *et al.* (2019) Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML *in vivo*. [Ann Hematol. 98 \(8\): 1905-18.](#)
78. Huber, L. *et al.* (2020) FGF Expression in HPV16-positive and -negative SCC After Treatment With Small-molecule Tyrosine Kinase Inhibitors and Everolimus. [Anticancer Res. 40 \(10\): 5621-30.](#)
79. Perut, F. *et al.* (2020) Citrate Supplementation Restores the Impaired Mineralisation Resulting from the Acidic Microenvironment: An In Vitro Study. [Nutrients. 12 \(12\): 3779.](#)
80. Estaras, M. *et al.* (2020) Melatonin modulates proliferation of pancreatic stellate cells through caspase-3 activation and changes in cyclin A and D expression. [J Physiol Biochem. 76 \(2\): 345-55.](#)
81. Pacheco, P.A.F. *et al.* (2020) Synthesis of new N,S-acetal analogs derived from

- juglone with cytotoxic activity against *Trypanosoma cruzi*. [J Bioenerg Biomembr. 52 \(3\): 199-213.](#)
82. Shechter, D. *et al.* (2020) Breast Cancer-Derived Microparticles Reduce Cancer Cell Adhesion, an Effect Augmented by Chemotherapy. [Cells. 9 \(10\) 2269.](#)
83. Gonzalez, A. *et al.* (2020) Melatonin modulates red-ox state and decreases viability of rat pancreatic stellate cells. [Sci Rep. 10 \(1\): 6352.](#)
84. Mojena-Medina, D. *et al.* (2020) Design, Implementation, and Validation of a Piezoelectric Device to Study the Effects of Dynamic Mechanical Stimulation on Cell Proliferation, Migration and Morphology. [Sensors \(Basel\). 20 \(7\): 2155.](#)
85. Ho, C.L. *et al.* (2020) Eucalyptus essential oils inhibit the lipopolysaccharide-induced inflammatory response in RAW264.7 macrophages through reducing MAPK and NF- $\kappa$ B pathways. [BMC Complement Med Ther. 20 \(1\): 200.](#)
86. Gloria, A. *et al.* (2020) Customised multiphasic nucleus/annulus scaffold for intervertebral disc repair/regeneration. [Connect Tissue Res. 61 \(2\): 152-62.](#)
87. Badwelan, M. *et al.* (2020) Poly( $\delta$ -valerolactone)/Poly(ethylene-co-vinylalcohol)/ $\beta$ -Tricalcium Phosphate Composite as Scaffolds: Preparation, Properties, and *In Vitro* Amoxicillin Release. [Polymers \(Basel\). 13\(1\):46.](#)
88. Wu, L. *et al.* (2020) Human airway-like multilayered tissue on 3D-TIPS printed thermoresponsive elastomer/collagen hybrid scaffolds. [Acta Biomater. 113: 177-95.](#)
89. Huang, C.L. *et al.* (2020) Antimicrobial Activity of Electrospun Polyvinyl Alcohol Nanofibers Filled with Poly[2-(tert-butylaminoethyl) Methacrylate]-Grafted Graphene Oxide Nanosheets. [Polymers \(Basel\). 28;12\(7\):1449.](#)
90. Jiménez-Holguín, J. *et al.* (2020) Strontium-Modified Scaffolds Based on Mesoporous Bioactive Glasses/Polyvinyl Alcohol Composites for Bone Regeneration. [Materials \(Basel\). 13\(23\):5526.](#)
91. Yang, P.M. *et al.* (2020) Carbon monoxide-releasing molecules protect against blue light exposure and inflammation in retinal pigment epithelial cells. [Int J Mol Med. 46 \(3\): 1096-106.](#)
92. Ansari, Z. *et al.* (2020) *In-Situ* Synthesis and Characterization of Chitosan/Hydroxyapatite Nanocomposite Coatings to Improve the Bioactive Properties of Ti6Al4V Substrates. [Materials \(Basel\). 13\(17\):3772.](#)
93. Alhuthali, H.M. *et al.* (2020) The natural alkaloid Jerantinine B has activity in acute myeloid leukemia cells through a mechanism involving c-Jun. [BMC Cancer. 20 \(1\): 629.](#)
94. Fatima, S. *et al.* (2021) Selenium Nanoparticles by Moderating Oxidative Stress Promote Differentiation of Mesenchymal Stem Cells to Osteoblasts. [Int J Nanomedicine. 16: 331-43.](#)
95. Peluso, V. *et al.* (2021) Impact of Magnetic Stimulation on Periodontal Ligament Stem Cells [International Journal of Molecular Sciences. 23 \(1\): 188.](#)
96. Hamann, M.V. *et al.* (2021) Transcriptional behavior of the HIV-1 promoter in context of the BACH2 prominent proviral integration gene. [Virus Res. 293: 198260.](#)
97. Pham, M.H. & Mancianti, F. (2021) *In Vitro* Antiviral Activity of Green Tea Polyphenon-60 against Avian Paramyxoviruses [Vet Med Int. 2021: 1-8.](#)
98. Kant, R. *et al.* (2021) Discovery of an Orally Efficacious MYC Inhibitor for Liver Cancer Using a GNMT-Based High-Throughput Screening System and Structure-Activity Relationship Analysis. [J Med Chem. 64 \(13\): 8992-9009.](#)
99. Caro-Briones, R. *et al.* (2021) Influence of Carbon Nanotubes Concentration on Mechanical and Electrical Properties of Poly(styrene-co-acrylonitrile) Composite Yarns

- Electrospun. [Polymers \(Basel\). 13 \(21\): 3655.](#)
100. Davidov, T. *et al.* (2021) Extracellular Matrix Hydrogels Originated from Different Organs Mediate Tissue-Specific Properties and Function. [Int J Mol Sci.22 \(21\): 11624.](#)
101. Yano, K. *et al.* (2021) Functional Alterations of Multidrug Resistance-Associated Proteins 2 and 5, and Breast Cancer Resistance Protein upon Snail-Induced Epithelial-Mesenchymal Transition in HCC827 Cells. [Biol Pharm Bull. 44 \(1\): 103-11.](#)
102. Cheng, S. *et al.* (2021) Pure Mg–Al Layered Double Hydroxide Film on Magnesium Alloys for Orthopedic Applications [ACS Omega. 6 \(38\): 24575-84.](#)
103. Silva, T.B. *et al.* (2021) Synthesis and *in vitro* and *in silico* studies of 1H- and 2H-1,2,3-triazoles as antichagasic agents. [Bioorg Chem. 116: 105250.](#)
104. Liu, Z. *et al.* (2021) Distinct BTK inhibitors differentially induce apoptosis but similarly suppress chemotaxis and lipid accumulation in mantle cell lymphoma. [BMC Cancer. 21 \(1\): 732.](#)
105. Imieje, V.O. *et al.* (2021) Antileishmanial Derivatives of Humulene from *Asteriscus hierochunticus*. with *in silico*. Tubulin Inhibition Potential [Records of Natural Products. \(2\): 150-71.](#)
106. Pagani, S. *et al.* (2021) Mechanical and *in vitro* biological properties of uniform and graded Cobalt-chrome lattice structures in orthopedic implants. [J Biomed Mater Res B Appl Biomater. 109 \(12\): 2091-103.](#)
107. Almeshari, A. *et al.* (2022) The additive effect of iloprost on the biological properties of Mineral trioxide aggregate on mesenchymal stem cells [Journal of Dental Sciences. 17 \(1\): 225-32.](#)
108. Cometa, S. *et al.* (2021) A 3D Printed Composite Scaffold Loaded with Clodronate to Regenerate Osteoporotic Bone: *In Vitro* Characterization. [Polymers \(Basel\). 13\(1\):150.](#)
109. Soriente, A. *et al.* (2022) Chitosan/hydroxyapatite nanocomposite scaffolds to modulate osteogenic and inflammatory response. [J Biomed Mater Res A. 110 \(2\): 266-72.](#)
110. Friesen, A. *et al.* (2022) Comparing  $\alpha$ -Quartz-Induced Cytotoxicity and Interleukin-8 Release in Pulmonary Mono- and Co-Cultures Exposed under Submerged and Air-Liquid Interface Conditions. [Int J Mol Sci. 23 \(12\): 6412.](#)
111. Chang, K. *et al.* (2022) Effects of Temoporfin-Based Photodynamic Therapy on the *In Vitro* Antibacterial Activity and Biocompatibility of Gelatin-Hyaluronic Acid Cross-Linked Hydrogel Membranes [Pharmaceutics. 14 \(11\): 2314.](#)
112. Chianese, G. *et al.* (2022) ROS-Generating Hyaluronic Acid-Modified Zirconium Dioxide-Acetylacetonate Nanoparticles as a Theranostic Platform for the Treatment of Osteosarcoma. [Nanomaterials \(Basel\). 13\(1\):54.](#)
113. Miles, C.E. *et al.* (2022) Polymer Texture Influences Cell Responses in Osteogenic Microparticles. [Cell Mol Bioeng. 15 \(5\): 409-23.](#)
114. Boanini, E. *et al.* (2022) Monetite vs. Brushite: Different Influences on Bone Cell Response Modulated by Strontium Functionalization. [J Funct Biomater. 13\(2\):65.](#)
115. Rosellini, E. *et al.* (2022) Biomimetic and Bioactive Small Diameter Tubular Scaffolds for Vascular Tissue Engineering. [Biomimetics \(Basel\). 7 \(4\): 199.](#)
116. Alfawaz, A. *et al.* (2022) Smart Nanocarrier Based on Poly(oligo(ethylene glycol) methyl ether acrylate) Terminated pH-Responsive Polymer Brushes Grafted Mesoporous Silica Nanoparticles [Applied Sciences. 12 \(7\): 3688.](#)
117. Aljarbou, F. *et al.* (2022) Efficacy of *Salvadora persica*. Root Extract as an Endodontic Irrigant- An *In-vitro*. evaluation [J Herb Med: 100564.](#)
118. Pakamwong, B. *et al.* (2022) Identification of Potent DNA Gyrase Inhibitors Active



- against *Mycobacterium tuberculosis*. [J Chem Inf Model. 62 \(7\): 1680-90.](#)
119. Taler, M. *et al.* (2022) Complex Effects of Sertraline and Citalopram on *In Vitro*. Murine Breast Cancer Proliferation and on *In Vivo*. Progression and Anxiety Level. [Int J Mol Sci. 23 \(5\): 2711.](#)
120. Kelleher, S. (2022) Loss-of-function SLC30A2 mutants are associated with gut dysbiosis and alterations in intestinal gene expression in preterm infants [Gut Microbes 14 \(1\): 2014739.](#)
121. Srivastava, G.K. *et al.* (2022) Factors influencing mesenchymal stromal cells in *in vitro* cellular models to study retinal pigment epithelial cell rescue. [Hum Cell. 35 \(4\): 1005-15.](#)
122. Mariani, E. *et al.* (2023) Pure Platelet and Leukocyte–Platelet-Rich Plasma for Regenerative Medicine in Orthopedics—Time- and Preparation-Dependent Release of Growth Factors and Effects on Synovial Fibroblasts: A Comparative Analysis [Int J Mol Sci. 24 \(2\): 1512.](#)
123. Liu, J. *et al.* (2022) Ibrutinib Inhibits Angiogenesis and Tumorigenesis in a BTK-Independent Manner. [Pharmaceutics. 14\(9\):1876.](#)
124. Tuna, T. *et al.* (2023) Effect of Hydrogen Peroxide on the Surface and Attractiveness of Various Zirconia Implant Materials on Human Osteoblasts: An *In Vitro* Study [Materials. 16 \(3\): 961.](#)
125. Alharbi, Z. *et al.* (2023) The LipoDerm Method for Regeneration and Reconstruction in Plastic Surgery: A Technical Experimental *Ex Vivo* Note [Medical Sciences. 11 \(1\): 16.](#)
126. Alanazi, S. (2022) Antineoplastic and Antitrypanosomal Properties of Propolis from *Tetragonula biroi* Friese. [Molecules.27 \(21\): 7463.](#)
127. Al-Hamoudi, F. *et al.* (2022) Bioactive Composite for Orbital Floor Repair and Regeneration. [Int J Mol Sci. 23\(18\):10333.](#)
128. Habita Habit A.H. *et al.* (2023) Evaluation of synergistic bioinhibitory effect between low-level laser irradiation and gold nanoparticles on MCF-7 cell line [J Nanopart Res. 25, 44](#)
129. Lee, T.Y. *et al.* (2023) Anti-microRNA-1976 as a Novel Approach to Enhance Chemosensitivity in XAF1(+) Pancreatic and Liver Cancer. [Biomedicines. 11 \(4\): 1136.](#)
130. Machado, I. *et al.* (2023) Marine Gelatin-Methacryloyl-Based Hydrogels as Cell Templates for Cartilage Tissue Engineering. [Polymers \(Basel\). 15 \(7\): 1674.](#)
131. Hsiao, L.C. *et al.* (2014) Murine cardiosphere-derived cells are impaired by age but not by cardiac dystrophic dysfunction. [Stem Cells Dev. 23 \(9\): 1027-36.](#)
132. Justin, A.W. *et al.* (2023) Densified collagen tubular grafts for human tissue replacement and disease modelling applications [Biomaterials Advances. 145: 213245.](#)
133. Kamsri, B. *et al.* (2023) Bioisosteric Design Identifies Inhibitors of *Mycobacterium tuberculosis* DNA Gyrase ATPase Activity. [J Chem Inf Model. 63 \(9\): 2707-18.](#)
134. Pablos, J.L. *et al.* (2023) New Photocrosslinked 3D Foamed Scaffolds Based on GelMA Copolymers: Potential Application in Bone Tissue Engineering. [Gels. 9 \(5\): 403.](#)
135. Radwan, A.B. *et al.* (2023) Evaluation of the Influence of Eggshell (ES) Concentration on the Degradation Behavior of Mg-2.5Zn Biodegradable Alloy in Simulated Body Fluid. [ACS Biomater Sci Eng. 9 \(5\): 2376-2391.](#)
136. Muthurangan, M. *et al.* (2023) Transient downregulation of NR4A1 leads to impaired osteoblast differentiation through the TGF- $\beta$  pathway, and Elesclomol (STA-4783) rescues this phenotype. [Cell Biochem Funct. 41 \(5\): 590-8.](#)
137. Vozovyk, K. *et al.* (2023) Effect of Cryoprotective Solutions on Metabolic Activity of

*Chlorococcum dissectum* and *Dunaliella salina* Cell Cultures [Problems of Cryobiology and Cryomedicine. 33 \(1\): 14-24.](#)

138. Lin, K.M. *et al.* (2023) Upregulation of IQGAP2 by EBV transactivator Rta and its influence on EBV life cycle. [J Virol. 97 \(8\): e0054023.](#)
139. Itoh, Y. *et al.* (2023) Discovery of Selective Histone Deacetylase 1 and 2 Inhibitors: Screening of a Focused Library Constructed by Click Chemistry, Kinetic Binding Analysis, and Biological Evaluation. [J Med Chem. Oct 17 \[Epub ahead of print\].](#)
140. Jiménez-Holguín, J. *et al.* (2024) Osteogenic-angiogenic coupled response of cobalt-containing mesoporous bioactive glasses *in vivo*. [Acta Biomater. S1742-7061\(24\)00003-5.](#)
141. Hur, J.Y. *et al.* (2020) The innate immunity protein IFITM3 modulates  $\gamma$ -secretase in Alzheimer's disease. [Nature. 586 \(7831\): 735-40.](#)
142. Alhamoudi, H.F. (2024) The role of fabrication methods and the impact of hydroxyapatite content on PU/HA scaffolds for tissue regeneration [Journal of Materials Research. \[Epub ahead of print\].](#)
143. Whitcomb, A. *et al.* (2024) Response Surface Methodology Optimizes Selenium Inhibition of Prostate Cancer PC-3 Cell Viability [Journal of Trace Elements in Medicine and Biology. : 127414.](#)
144. Habita Habit, H, A. *et al.* (2023) Evaluation of synergistic bioinhibitory effect between low-level laser irradiation and gold nanoparticles on MCF-7 cell line [Journal of Nanoparticle Research. 25 \(3\) 28 Feb \[Epub ahead of print\].](#)
145. Cooper, E. *et al.* (2023) Elucidating the cellular uptake mechanisms of heptamethine cyanine dye analogues for their use as an anticancer drug-carrier molecule for the treatment of glioblastoma. [Chem Biol Drug Des. 101 \(3\): 696-716.](#)
146. Kasprzak, A. *et al.* (2023) Oxidation-derived anticancer potential of sumanene-ferrocene conjugates. [Dalton Trans. 53 \(1\): 56-64.](#)
147. Hou, Z. *et al.* (2024) Plasma bias homopolar sputtering technology and its application to enhance bioactivity of polyetheretherketone surface [Surfaces and Interfaces. : 104249.](#)
148. Wong, W. *et al.* (2024) Antcin-H, a natural triterpene derived from *Anrodia cinnamomea*, ameliorates dextran sulfate sodium-induced colitis in mice by inhibiting the NLRP3 inflammasome [Journal of Traditional and Complementary Medicine. 30 Mar \[Epub ahead of print\].](#)
149. Deken, M.M. *et al.* (2020) Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session. [J Control Release. 323: 269-81.](#)
150. Madadi-Goli, N. *et al.* (2024) The importance of heteroresistance and efflux pumps in bedaquiline-resistant *Mycobacterium tuberculosis* isolates from Iran. [Ann Clin Microbiol Antimicrob. 23 \(1\): 36.](#)
151. Huang, S. *et al.* (2024) Cellular experimental study and mechanism of surface modification of 3D printed titanium materials to modulate the sealing and antimicrobial properties of oral implants [European Journal of Inflammation. 7 May \[Epub ahead of print\].](#)
152. Novello, E. *et al.* (2024) Synthesis, Characterisation, and *In Vitro* Evaluation of Biocompatibility, Antibacterial and Antitumor Activity of Imidazolium Ionic Liquids [Pharmaceutics. 16 \(5\): 642.](#)
153. Huang, S. *et al.* (2024) Cellular experimental study and mechanism of surface modification of 3D printed titanium materials to modulate the sealing and antimicrobial properties of oral implants [Eur J Inflamm. 22; 7 May \[Epub ahead of print\].](#)
154. Knowles, H.J. *et al.* (2023) Mature primary human osteocytes in mini organotypic

- cultures secrete FGF23 and PTH1-34-regulated sclerostin. [Front Endocrinol \(Lausanne\). 14: 1167734.](#)
155. García-Lamas, L. *et al.* (2024) In vivo behavior in rabbit radius bone defect of scaffolds based on nanocarbonate hydroxyapatite. [J Biomed Mater Res B Appl Biomater. 112 \(2\): e35391.](#)
156. Novello, E. *et al.* (2024) Synthesis, Characterisation, and In Vitro Evaluation of Biocompatibility, Antibacterial and Antitumor Activity of Imidazolium Ionic Liquids. [Pharmaceutics. 16 \(5\): 642.](#)
157. Su, A-J.A. *et al.* (2023) Fibrous polypeptide based bioscaffold delivery of minocycline hydrochloride for nerve regeneration [Materials Chemistry and Physics. 305: 127974.](#)
158. Chen, Y.C. *et al.* (2024) Human platelet lysate-cultured adipose-derived stem cell sheets promote angiogenesis and accelerate wound healing via CCL5 modulation. [Stem Cell Res Ther. 15 \(1\): 163.](#)
159. Salamanna, F. *et al.* (2024) A Pilot Study on Circulating, Cellular, and Tissue Biomarkers in Osteosarcomenic Patients. [Int J Mol Sci. 25 \(11\): 5879.](#)

---

**Further Reading** 1. Rampersad SN (2012) Multiple applications of Alamar Blue as an indicator of metabolic function and cellular health in cell viability bioassays. [Sensors \(Basel\). 12 \(9\): 12347-60.](#)

---

**Storage** Store at +4°C. DO NOT FREEZE.  
This product should be stored undiluted. This product is photosensitive and should be protected from light.

---

**Guarantee** Guaranteed until date of expiry. Please see product label.

---

**Acknowledgements** Manufactured for Bio-Rad by Trek Diagnostic System. U.S. patent 5,501,959.

---

**Health And Safety Information** Material Safety Datasheet documentation #10289 available at: <https://www.bio-rad-antibodies.com/SDS/BUF012B>  
10289

---

**Regulatory** For research purposes only.

## Related Products

### Recommended Useful Reagents

[alamarBlue® \(BUF012A\)](#)

**North & South** Tel: +1 800 265 7376

**America** Fax: +1 919 878 3751

Email: [antibody\\_sales\\_us@bio-rad.com](mailto:antibody_sales_us@bio-rad.com)

**Worldwide**

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: [antibody\\_sales\\_uk@bio-rad.com](mailto:antibody_sales_uk@bio-rad.com)

**Europe**

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: [antibody\\_sales\\_de@bio-rad.com](mailto:antibody_sales_de@bio-rad.com)

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://www.bio-rad-antibodies.com/datasheets)

'M411848:221107'

**Printed on 21 Jun 2024**